High Prices & No Excuses: 6 Anticompetitive Games (Presentation Slides)
Testimony for FTC Workshop on “Understanding Competition in Prescription Drug Markets”, 2017
10 Pages Posted: 8 Nov 2017
Date Written: November 6, 2017
Brand firms have delayed generic competition even when there are no (or weak) patents. This testimony to the FTC highlights 6 such behaviors: (1) pay-for-delay settlements, (2) product hopping, (3) citizen petitions, (4) "REMS" restrictions, (5) non-REMS distribution restrictions, and (6) bundling/rebates. The testimony concludes with proposals addressing these forms of conduct.
Keywords: Drugs, Pharmaceuticals, Patent, Antitrust
JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38
Suggested Citation: Suggested Citation